Riskpilot← Back to searchSign inGet full accessGlycoprobe AB
ABActiveOrg 5567295216Scheelevägen 27Research and experimental development on natural sciences and engineering · NACE 7210Est. 20076 employees
Revenue 2024
SEK 9,9M
-13% vs 2023
EBITDA margin
13.2%
-2% vs 2023
Equity ratio
16.9%
Financial strength
Net profit 2024
SEK 296K
+104% vs 2023
| Revenue | SEK 9,9M | -13% |
| EBITDA | SEK 1,3M | -2% |
| Net profit | SEK 296K | +104% |
| Total assets | SEK 12,8M | -10% |
| Equity | SEK 2,2M | +16% |
| Employees | 6 | — |
Legal name
Glycoprobe AB
Org number
5567295216
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 maj 2007
Share capital
SEK 100 000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolagets verksamhetska vara forskning, utveckling och tillverkning av kolhydratbaserade produkter inom bioteknik- och medicinteknikbranschen, ävensom idka därmed förenlig verksamhet.
Address
Scheelevägen 27
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 9 506 | 8 804 | 7 876 | 7 882 | 9 618 | 11 378 | 9 867 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 1 006 | 1 996 | 1 609 | 2 266 | 2 003 | 723 | 102 | 1 798 | 1 322 | 1 299 |
| Depreciation & amort. | −804 | −810 | −812 | −694 | −510 | −1 172 | −1 449 | −1 495 | −8 131 | −1 277 |
| EBIT | 202 | 1 186 | 797 | 1 572 | 1 493 | −449 | −1 347 | 303 | −6 809 | 22 |
| Net financials | −2 | −5 | −9 | −3 | −3 | — | −8 | −30 | −40 | −22 |
| Profit before tax | 0 | 155 | −30 | −4 | −3 | −403 | 0 | 0 | −6 849 | 296 |
| Tax | −0 | −45 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | 110 | −30 | −4 | −3 | −403 | 0 | 0 | −6 849 | 296 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 18 966 | 19 372 | 18 727 | 19 069 | 19 276 | 19 722 | 20 426 | 21 120 | 14 131 | 12 757 |
| Equity | 1 030 | 1 140 | 1 412 | 1 767 | 2 259 | 1 856 | 1 856 | 1 856 | 1 856 | 2 152 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 832 | 555 | 277 | 0 |
| Short-term debt | 16 736 | 17 382 | 16 600 | 16 849 | 16 709 | 17 605 | 17 152 | 17 851 | 11 139 | 10 042 |
| Total debt | 16 736 | 17 382 | 16 600 | 16 849 | 16 709 | 17 605 | 17 984 | 18 406 | 11 416 | 10 042 |
EBITDA margin
13.2%
This company
15.8%
Market median
-16% vs market
20152024
Equity ratio
16.9%
This company
38.2%
Market median
-56% vs market
20152024
Return on equity
13.8%
This company
18.4%
Market median
+25% vs market
20152024
Net profit margin
3.0%
This company
8.1%
Market median
-63% vs market
20152024
Asset turnover
0.77×
This company
1.12×
Market median
-31% vs market
20152024
Debt / equity
4.93×
This company
0.62×
Market median
-695% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PM Chief Auditor | Chief Auditor | 2022 | — | — |
OC Chief Auditor | Chief Auditor | 2022 | — | — |
KG Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2024 | — | — | |
| Deputy Board Member | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Glycorex Transplantation AB (publ) | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Glycorex Transplantation AB (publ)
Glycoprobe AB Board members of Glycoprobe AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Martin Henriksson | Chief Auditor | 0 companies |
| Ola Christopher Carelius Larsmon | Chief Auditor | 0 companies |
| Kurt Gösta Ingemar Nilsson | Chief Executive Officer | 0 companies |
| Anna Maria Ternéus Laurin | Deputy Board Member | 0 companies |
| Claes Gustav Tyko Blanche | Deputy Board Member | 0 companies |